Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 10/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859191 | 0.91 | TRPV1 (0.44) | DCUN1D1TRPV1UBE2MALDH1A1LMNA | |
| SCHEMBL3857471 | 0.89 | TRPV1 (0.45) | DCUN1D1TRPV1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3866316 | 0.85 | TRPV1 (0.41) | TRPV1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL3863730 | 0.84 | LMNA (0.45) | TRPV1ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL13683425 | 0.82 | KDM4E (0.46) | KMT2A | |
| SCHEMBL3866529 | 0.81 | HTR2A (0.44) | ALDH1A1SMN1; SMN2CYP2C9KMT2A | |
| SCHEMBL3861755 | 0.80 | TRPV1 (0.46) | TRPV1POLBPTGDR2 | |
| SCHEMBL4009965 | 0.79 | DCUN1D1 (0.47) | DCUN1D1UBE2MALDH1A1LMNAMAPT | |
| SCHEMBL4011914 | 0.79 | DCUN1D1 (0.47) | DCUN1D1UBE2MALDH1A1LMNAMAPT | |
| SCHEMBL4017743 | 0.79 | ACHE (0.48) | DCUN1D1UBE2MALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-7592373-B2 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-22 | — | — | US | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | DCUN1D1 3160/4885TRPV1 1200/4885UBE2M 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.